Haruki et al. demonstrated that a dominant-negative Notch-3 receptor, capable of inhibiting the Notch-3 pathway, was effective in reducing soft agar growth of human lung cancer lines and sensitized these lines to subsequent EGF receptor tyrosine kinase inhibition treatment [87]. Here, NOTCH3 is linked to lung carcinoma.